Sevirumab

Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV) . Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2].

Product Specifications

CAS Number

[138660-96-5]

Product Name Alternative

MSL-109

UNSPSC

12352203

Target

CMV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/sevirumab.html

Purity

99.9

Solubility

H2O

Smiles

[Sevirumab]

Molecular Weight

(148.49 kDa)

References & Citations

[1]Nokta M, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109) : enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res. 1994 May;24 (1) :17-26.|[2]Fouts AE, et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A. 2014 Jun 3;111 (22) :8209-14.